Abstract.
In this study we evaluated whether positron emission tomography (PET) using the amino acid [11C]methyl-L-methionine (MET) may be used for therapy monitoring in patients with rectal cancer who are undergoing preoperative chemoradiotherapy. A total of 41 MET-PET scans were performed in 26 patients with locally advanced rectal cancers. All patients were examined prior to chemoradiotherapy. In 15 patients, MET-PET was repeated after preoperative chemoradiotherapy (45 Gy radiation dose, 250 mg 5-fluorouracil as continuous infusion). MET uptake prior to and after the completion of chemoradiotherapy was correlated with changes in T stage and histopathological regression. All tumours were visualised with high contrast and had a significantly higher SUV (5.7±2.2) than normal rectum (2.7±0.9) and all other organs in the field of view except the small intestine (3.9±1.7). In all tumours studied prior to and after chemoradiotherapy, MET uptake decreased during therapy (SUV before therapy, 6.2±2.3; SUV after therapy, 2.6±1.2; P=0.0007). However, the degree of change in MET uptake was not correlated with histopathological tumour response. In conclusion, primary rectal cancer can be imaged with MET-PET. However, for the studied chemoradiotherapy regimen, MET-PET did not allow an assessment of the response to therapy.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 2 November 2001 and in revised form 27 January 2002
Electronic Publication
Rights and permissions
About this article
Cite this article
Wieder, H., Ott, K., Zimmermann, F. et al. PET imaging with [11C]methyl-L-methionine for therapy monitoring in patients with rectal cancer. Eur J Nucl Med 29, 789–796 (2002). https://doi.org/10.1007/s00259-002-0779-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-002-0779-4